603077:SSESichuan Hebang Biotechnology Co. Ltd. Class A Analysis

Technical signals show the stock is oversold (RSI ~28) and the MACD is bearish, with price hovering just above the identified support of 2.23 CNY. Fundamentally, the company posted a 19.6% revenue decline, negative profit margin (-5.5%), and a very high debt‑to‑equity ratio (~50), while forward earnings suggest a modest PE of 3.4. The DCF‑derived fair value (~0.03 CNY) is dramatically lower than the current price (2.31 CNY), indicating a sizable valuation gap. Volatility is elevated at 33% over 30 days, though beta is low (0.38), and trading volume has been decreasing, raising liquidity concerns. Overall, the stock appears priced well above intrinsic estimates despite weak earnings and substantial leverage.